Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 23 of 23 entries
Sorted by: Best Match Show Resources per page
The Use of Primary Care Electronic Health Records for Research: Lipid Medications and Mortality in Elderly Patients.

Pharmacy (Basel, Switzerland)

Hodgkins AJ, Mullan J, Mayne D, Bonney A.
PMID: 31540408
Pharmacy (Basel). 2019 Sep 18;7(3). doi: 10.3390/pharmacy7030134.

General practice electronic health record (EHR) data have significant potential for clinical research. This study demonstrates the feasibility of utilising longitudinal EHR data analysis to address clinically relevant outcomes and uses the relationship between lipid medication prescription and all-cause...

Cite
Hodgkins AJ, Mullan J, Mayne D, et al. The Use of Primary Care Electronic Health Records for Research: Lipid Medications and Mortality in Elderly Patients. Pharmacy (Basel). 2019;7(3)doi: 10.3390/pharmacy7030134.
Hodgkins, A. J., Mullan, J., Mayne, D., & Bonney, A. (2019). The Use of Primary Care Electronic Health Records for Research: Lipid Medications and Mortality in Elderly Patients. Pharmacy (Basel, Switzerland), 7(3), . https://doi.org/10.3390/pharmacy7030134
Hodgkins, Adam J, et al. "The Use of Primary Care Electronic Health Records for Research: Lipid Medications and Mortality in Elderly Patients." Pharmacy (Basel, Switzerland) vol. 7,3 (2019). doi: https://doi.org/10.3390/pharmacy7030134
Hodgkins AJ, Mullan J, Mayne D, Bonney A. The Use of Primary Care Electronic Health Records for Research: Lipid Medications and Mortality in Elderly Patients. Pharmacy (Basel). 2019 Sep 18;7(3). doi: 10.3390/pharmacy7030134. PMID: 31540408; PMCID: PMC6789657.
Copy Download .nbib Format: NLM
A comparative study of omega-3-fatty acids obtained from marine fish and bezafibrate alone and in combination as hypolipidemic agents.

Pakistan journal of pharmaceutical sciences

Saify ZS, Hassan S, Arif M, Ahmad F, Chishti KA, Siddiqui S.
PMID: 16414833
Pak J Pharm Sci. 2000 Jan;13(1):1-11.

The fish oil and its constituents have been studied in detail with special reference to ailments. The discovery of omega-3 fatty acids led to a detailed investigation about its effect and role as anti-cholesterolemic agents. The effect of fish...

Cite
Saify ZS, Hassan S, Arif M, et al. A comparative study of omega-3-fatty acids obtained from marine fish and bezafibrate alone and in combination as hypolipidemic agents. Pak J Pharm Sci. 2000;13(1):1-11
Saify, Z. S., Hassan, S., Arif, M., Ahmad, F., Chishti, K. A., & Siddiqui, S. (2000). A comparative study of omega-3-fatty acids obtained from marine fish and bezafibrate alone and in combination as hypolipidemic agents. Pakistan journal of pharmaceutical sciences, 13(1), 1-11.
Saify, Z S, et al. "A comparative study of omega-3-fatty acids obtained from marine fish and bezafibrate alone and in combination as hypolipidemic agents." Pakistan journal of pharmaceutical sciences vol. 13,1 (2000): 1-11.
Saify ZS, Hassan S, Arif M, Ahmad F, Chishti KA, Siddiqui S. A comparative study of omega-3-fatty acids obtained from marine fish and bezafibrate alone and in combination as hypolipidemic agents. Pak J Pharm Sci. 2000 Jan;13(1):1-11. PMID: 16414833.
Copy Download .nbib Format: NLM
Renal effects of PPARalpha-agonists.

Minerva urologica e nefrologica = The Italian journal of urology and nephrology

Izzedine H, Launay-Vacher V, Baumelou A, Deray G.
PMID: 15785426
Minerva Urol Nefrol. 2004 Dec;56(4):339-42.

Peroxisome proliferator-activated receptor alpha (PPARalpha) is a member of the large nuclear receptor superfamily. Its main role is to activate genes involved in fatty acid oxidation in the liver, heart, kidney and skeletal muscle. While they are mainly used...

Cite
Izzedine H, Launay-Vacher V, Baumelou A, et al. Renal effects of PPARalpha-agonists. Minerva Urol Nefrol. 2004;56(4):339-42
Izzedine, H., Launay-Vacher, V., Baumelou, A., & Deray, G. (2004). Renal effects of PPARalpha-agonists. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 56(4), 339-42.
Izzedine, H, et al. "Renal effects of PPARalpha-agonists." Minerva urologica e nefrologica = The Italian journal of urology and nephrology vol. 56,4 (2004): 339-42.
Izzedine H, Launay-Vacher V, Baumelou A, Deray G. Renal effects of PPARalpha-agonists. Minerva Urol Nefrol. 2004 Dec;56(4):339-42. PMID: 15785426.
Copy Download .nbib Format: NLM
The hypolipidemic activity of boronated nucleosides in male mice and rats.

Metal-based drugs

Burnham BS, Sood A, Tomasz J, Powell WJ, Spielvogel BF, Chen SY, Hall IH.
PMID: 18475753
Met Based Drugs. 1996;3(4):173-83. doi: 10.1155/MBD.1996.173.

The boronated nucleosides with varying bases and sugar moieties were shown to be potent hypolipidemic agents in rodents. The 3'- aminocynaoborane dideoxythymidine derivative caused reductions in serum cholesterol and triglyceride levels, tissue lipids, VLDL and LDL cholesterol levels while...

Cite
Burnham BS, Sood A, Tomasz J, et al. The hypolipidemic activity of boronated nucleosides in male mice and rats. Met Based Drugs. 1996;3(4):173-83doi: 10.1155/MBD.1996.173.
Burnham, B. S., Sood, A., Tomasz, J., Powell, W. J., Spielvogel, B. F., Chen, S. Y., & Hall, I. H. (1996). The hypolipidemic activity of boronated nucleosides in male mice and rats. Metal-based drugs, 3(4), 173-83. https://doi.org/10.1155/MBD.1996.173
Burnham, B S, et al. "The hypolipidemic activity of boronated nucleosides in male mice and rats." Metal-based drugs vol. 3,4 (1996): 173-83. doi: https://doi.org/10.1155/MBD.1996.173
Burnham BS, Sood A, Tomasz J, Powell WJ, Spielvogel BF, Chen SY, Hall IH. The hypolipidemic activity of boronated nucleosides in male mice and rats. Met Based Drugs. 1996;3(4):173-83. doi: 10.1155/MBD.1996.173. PMID: 18475753; PMCID: PMC2365024.
Copy Download .nbib Format: NLM
Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes.

Clinical pharmacology : advances and applications

Di Pierro F, Putignano P, Villanova N, Montesi L, Moscatiello S, Marchesini G.
PMID: 24277991
Clin Pharmacol. 2013 Nov 19;5:167-74. doi: 10.2147/CPAA.S54308. eCollection 2013.

BACKGROUND: Berberine is an isoquinoline alkaloid widely used to improve the glucidic and lipidic profiles of patients with hypercholesterolemia, metabolic syndrome, and type 2 diabetes. The limitation of berberine seems to be its poor oral bioavailability, which is affected...

Cite
Di Pierro F, Putignano P, Villanova N, et al. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol. 2013;5:167-74doi: 10.2147/CPAA.S54308.
Di Pierro, F., Putignano, P., Villanova, N., Montesi, L., Moscatiello, S., & Marchesini, G. (2013). Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clinical pharmacology : advances and applications, 5167-74. https://doi.org/10.2147/CPAA.S54308
Di Pierro, Francesco, et al. "Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes." Clinical pharmacology : advances and applications vol. 5 (2013): 167-74. doi: https://doi.org/10.2147/CPAA.S54308
Di Pierro F, Putignano P, Villanova N, Montesi L, Moscatiello S, Marchesini G. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol. 2013 Nov 19;5:167-74. doi: 10.2147/CPAA.S54308. eCollection 2013. PMID: 24277991; PMCID: PMC3838471.
Copy Download .nbib Format: NLM
The impact of hypotestosteronemia on cardiometabolic effects of atorvastatin in men with hypercholesterolemia: a pilot study.

Coronary artery disease

Krysiak R, Kowalcze K, Okopień B.
PMID: 33826536
Coron Artery Dis. 2021 Dec 01;32(8):706-712. doi: 10.1097/MCA.0000000000001031.

BACKGROUND: Hypothyroidism, hyperprolactinemia, macroprolactinemia and low vitamin D status were found to impair pleiotropic effects of hypolipidemic agents. The aim of the current study was to investigate whether cardiometabolic effects of atorvastatin in men are determined by endogenous testosterone.METHODS:...

Cite
Krysiak R, Kowalcze K, Okopień B. The impact of hypotestosteronemia on cardiometabolic effects of atorvastatin in men with hypercholesterolemia: a pilot study. Coron Artery Dis. 2021;32(8):706-712doi: 10.1097/MCA.0000000000001031.
Krysiak, R., Kowalcze, K., & Okopień, B. (2021). The impact of hypotestosteronemia on cardiometabolic effects of atorvastatin in men with hypercholesterolemia: a pilot study. Coronary artery disease, 32(8), 706-712. https://doi.org/10.1097/MCA.0000000000001031
Krysiak, Robert, et al. "The impact of hypotestosteronemia on cardiometabolic effects of atorvastatin in men with hypercholesterolemia: a pilot study." Coronary artery disease vol. 32,8 (2021): 706-712. doi: https://doi.org/10.1097/MCA.0000000000001031
Krysiak R, Kowalcze K, Okopień B. The impact of hypotestosteronemia on cardiometabolic effects of atorvastatin in men with hypercholesterolemia: a pilot study. Coron Artery Dis. 2021 Dec 01;32(8):706-712. doi: 10.1097/MCA.0000000000001031. PMID: 33826536.
Copy Download .nbib Format: NLM
Depressive symptoms and adherence to cardiometabolic therapies across phases of treatment among adults with diabetes: the Diabetes Study of Northern California (DISTANCE).

Patient preference and adherence

Bauer AM, Parker MM, Moffet HH, Schillinger D, Adler NE, Adams AS, Schmittdiel JA, Katon WJ, Karter AJ.
PMID: 28392679
Patient Prefer Adherence. 2017 Mar 24;11:643-652. doi: 10.2147/PPA.S124181. eCollection 2017.

OBJECTIVE: Among adults with diabetes, depression is associated with poorer adherence to cardiometabolic medications in ongoing users; however, it is unknown whether this extends to early adherence among patients newly prescribed these medications. This study examined whether depressive symptoms...

Cite
Bauer AM, Parker MM, Moffet HH, et al. Depressive symptoms and adherence to cardiometabolic therapies across phases of treatment among adults with diabetes: the Diabetes Study of Northern California (DISTANCE). Patient Prefer Adherence. 2017;11:643-652doi: 10.2147/PPA.S124181.
Bauer, A. M., Parker, M. M., Moffet, H. H., Schillinger, D., Adler, N. E., Adams, A. S., Schmittdiel, J. A., Katon, W. J., & Karter, A. J. (2017). Depressive symptoms and adherence to cardiometabolic therapies across phases of treatment among adults with diabetes: the Diabetes Study of Northern California (DISTANCE). Patient preference and adherence, 11643-652. https://doi.org/10.2147/PPA.S124181
Bauer, Amy M, et al. "Depressive symptoms and adherence to cardiometabolic therapies across phases of treatment among adults with diabetes: the Diabetes Study of Northern California (DISTANCE)." Patient preference and adherence vol. 11 (2017): 643-652. doi: https://doi.org/10.2147/PPA.S124181
Bauer AM, Parker MM, Moffet HH, Schillinger D, Adler NE, Adams AS, Schmittdiel JA, Katon WJ, Karter AJ. Depressive symptoms and adherence to cardiometabolic therapies across phases of treatment among adults with diabetes: the Diabetes Study of Northern California (DISTANCE). Patient Prefer Adherence. 2017 Mar 24;11:643-652. doi: 10.2147/PPA.S124181. eCollection 2017. PMID: 28392679; PMCID: PMC5373834.
Copy Download .nbib Format: NLM
The hypolipidemic activity of benzenetricarboxylic acids in rodents.

Pharmaceutical research

Hall IH, Chapman JM, Gilbert C.
PMID: 24277214
Pharm Res. 1984 Mar;1(2):63-8. doi: 10.1023/A:1016399213993.

A series of benzenetricarboxylic acids was shown to be potent hypolipidemic agents in rodents. Terephthalic acid proved to be one of the more potent agents, lowering serum cholesterol 42% and serum triglyceride 33 % at 20 mg/kg/day for 16...

Cite
Hall IH, Chapman JM, Gilbert C. The hypolipidemic activity of benzenetricarboxylic acids in rodents. Pharm Res. 1984;1(2):63-8doi: 10.1023/A:1016399213993.
Hall, I. H., Chapman, J. M., & Gilbert, C. (1984). The hypolipidemic activity of benzenetricarboxylic acids in rodents. Pharmaceutical research, 1(2), 63-8. https://doi.org/10.1023/A:1016399213993
Hall, I H, et al. "The hypolipidemic activity of benzenetricarboxylic acids in rodents." Pharmaceutical research vol. 1,2 (1984): 63-8. doi: https://doi.org/10.1023/A:1016399213993
Hall IH, Chapman JM, Gilbert C. The hypolipidemic activity of benzenetricarboxylic acids in rodents. Pharm Res. 1984 Mar;1(2):63-8. doi: 10.1023/A:1016399213993. PMID: 24277214.
Copy Download .nbib Format: NLM
Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy.

Journal of clinical and translational hepatology

Zhang QQ, Lu LG.
PMID: 26357637
J Clin Transl Hepatol. 2015 Mar;3(1):78-84. doi: 10.14218/JCTH.2014.00037. Epub 2015 Mar 15.

Studies have shown that nonalcoholic fatty liver disease (NAFLD) is strongly associated with several metabolic disorders and diseases, such as obesity, type 2 diabetes mellitus, and dyslipidemia. In NAFLD, dyslipidemia is manifested as increased serum triglyceride and low-density lipoprotein...

Cite
Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol. 2015;3(1):78-84doi: 10.14218/JCTH.2014.00037.
Zhang, Q. Q., & Lu, L. G. (2015). Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. Journal of clinical and translational hepatology, 3(1), 78-84. https://doi.org/10.14218/JCTH.2014.00037
Zhang, Qing-Qing, and Lu, Lun-Gen. "Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy." Journal of clinical and translational hepatology vol. 3,1 (2015): 78-84. doi: https://doi.org/10.14218/JCTH.2014.00037
Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol. 2015 Mar;3(1):78-84. doi: 10.14218/JCTH.2014.00037. Epub 2015 Mar 15. PMID: 26357637; PMCID: PMC4542078.
Copy Download .nbib Format: NLM
The hypolipidemic activity of metal complexes of amine carboxyboranes in rodents.

Metal-based drugs

Hall IH, Spielvogel BF, Sood A, Morse KW, Norwood Iii VM, Wong OT.
PMID: 18476247
Met Based Drugs. 1994;1(4):329-36. doi: 10.1155/MBD.1994.329.

The metal complexes of amine-carboxyborane including copper, chromium, zinc, calcium amd cobalt were effective hypolipidemic agents lowering both serum cholesterol and triglyceride levels significantly in mice at 8 mg/kg/day, I.P. after 16 days. The agents reduced acetyl CoA synthetase,...

Cite
Hall IH, Spielvogel BF, Sood A, et al. The hypolipidemic activity of metal complexes of amine carboxyboranes in rodents. Met Based Drugs. 1994;1(4):329-36doi: 10.1155/MBD.1994.329.
Hall, I. H., Spielvogel, B. F., Sood, A., Morse, K. W., Norwood Iii, V. M., & Wong, O. T. (1994). The hypolipidemic activity of metal complexes of amine carboxyboranes in rodents. Metal-based drugs, 1(4), 329-36. https://doi.org/10.1155/MBD.1994.329
Hall, I H, et al. "The hypolipidemic activity of metal complexes of amine carboxyboranes in rodents." Metal-based drugs vol. 1,4 (1994): 329-36. doi: https://doi.org/10.1155/MBD.1994.329
Hall IH, Spielvogel BF, Sood A, Morse KW, Norwood Iii VM, Wong OT. The hypolipidemic activity of metal complexes of amine carboxyboranes in rodents. Met Based Drugs. 1994;1(4):329-36. doi: 10.1155/MBD.1994.329. PMID: 18476247; PMCID: PMC2364912.
Copy Download .nbib Format: NLM
REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy.

Journal of lipid and atherosclerosis

Park SJ, Park DH.
PMID: 33024733
J Lipid Atheroscler. 2020 Sep;9(3):406-418. doi: 10.12997/jla.2020.9.3.406. Epub 2020 Sep 18.

Dyslipidemia refers to an abnormal amount of lipid in the blood, and the total cholesterol level is defined as the sum of high-density lipoprotein cholesterol, low-density lipoprotein (LDL) cholesterol, and very-LDL cholesterol concentrations. In Korea, the westernization of lifestyle...

Cite
Park SJ, Park DH. REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy. J Lipid Atheroscler. 2020;9(3):406-418doi: 10.12997/jla.2020.9.3.406.
Park, S. J., & Park, D. H. (2020). REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy. Journal of lipid and atherosclerosis, 9(3), 406-418. https://doi.org/10.12997/jla.2020.9.3.406
Park, Su Jin, and Park, Dong Ho. "REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy." Journal of lipid and atherosclerosis vol. 9,3 (2020): 406-418. doi: https://doi.org/10.12997/jla.2020.9.3.406
Park SJ, Park DH. REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy. J Lipid Atheroscler. 2020 Sep;9(3):406-418. doi: 10.12997/jla.2020.9.3.406. Epub 2020 Sep 18. PMID: 33024733; PMCID: PMC7521975.
Copy Download .nbib Format: NLM
Showing 13 to 23 of 23 entries